| 5.71 -0.17 (-2.89%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.62 |
1-year : | 8.56 |
| Resists | First : | 6.52 |
Second : | 7.32 |
| Pivot price | 6.27 |
|||
| Supports | First : | 5.22 |
Second : | 4.34 |
| MAs | MA(5) : | 5.84 |
MA(20) : | 6.34 |
| MA(100) : | 5.64 |
MA(250) : | 5.1 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 29 |
D(3) : | 26.6 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 7.36 | Low : | 2.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed above bottom band by 13.6%. Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.89 - 5.92 | 5.92 - 5.95 |
| Low: | 5.43 - 5.47 | 5.47 - 5.5 |
| Close: | 5.65 - 5.72 | 5.72 - 5.76 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Wed, 18 Feb 2026
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Wed, 18 Feb 2026
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
Mon, 16 Feb 2026
Solid Biosciences Insiders Sold US$823k Of Shares Suggesting Hesitancy - Sahm
Mon, 09 Feb 2026
Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus
Mon, 09 Feb 2026
Solid Bio aligns with FDA on late-stage trial design for Duchenne drug - Seeking Alpha
Mon, 09 Feb 2026
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 106.1 (%) |
| Shares Short | 8,600 (K) |
| Shares Short P.Month | 9,940 (K) |
| EPS | -2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.7 % |
| Return on Equity (ttm) | -86.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -2.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|